SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
RPRolando PajonNANicole A. Doria-RoseXSXiaoying ShenSDStephen D. SchmidtSOSijy O’Dell
Moderna Therapeutics (United States) · National Institute of Allergy and Infectious Diseases · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
389
total citations
- FWCI
- 38.81
- Percentile
- 100%
- References
- 5
Citations per year
Authors
47- RPRolando PajonCorresponding
Moderna Therapeutics (United States)
- NANicole A. Doria-Rose
National Institute of Allergy and Infectious Diseases
- XSXiaoying Shen
Duke Medical Center
- SDStephen D. Schmidt
ActionAid
- SOSijy O’Dell
ActionAid
Topics & keywords
Topics
Keywords
- Neutralization
- Vaccination
- Vaccination schedule
- Antibody
- Booster (rocketry)
No related works found for this paper.
Funding
- UDU.S. Department of Health and Human ServicesAward: 75A50120C00034
- MModerna
- NINational Institutes of HealthAwards: NIH UM1AI148684 (LG), NIH UM1 AI148689 (KL), NIH U19 AI142790 (BK), NIH UM1AI148575 (RLA), NIH 75N93019C00050 (DCM, XS)
- NINational Institute of Allergy and Infectious DiseasesAwards: UM1 AI 68636, UM1 AI 68635, UM1 AI 68618, UM1 AI148684-03, UM1 AI 68619